Rapid Development of Salivary Gland Carcinomas upon Conditional Expression of K-ras Driven by the Cytokeratin 5 Promoter
Ana R. Raimondi(Istituto De Angeli (Italy)), Alfredo Molinolo(University of San Diego)
Cited by 39
Related Papers
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
|The Lancet Oncology|2021|257